tesetaxel: Clinical Trials

18 trials of tesetaxel, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 unknown, 4 completed, 4 terminated. 12 Phase 2, 6 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 212Unknown 8, Completed 2, Terminated 2
Phase 16Unknown 3, Completed 2, Terminated 1
Phase 31Terminated 1

Follow tesetaxel: new trials by email Literature Review of tesetaxel trials Research Report on tesetaxel

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors
Tesetaxel, Itraconazole, Rifampin - Advanced Solid Tumors
Phase 1TerminatedOdonate Therapeutics, Inc.932020-03-062021-07-28
Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC
Tesetaxel, Nivolumab, Pembrolizumab - Breast Cancer
Phase 2TerminatedOdonate Therapeutics, Inc.2942019-07-092021-07-30
Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC
Tesetaxel, Capecitabine - Breast Cancer
Phase 2TerminatedOdonate Therapeutics, Inc.1522019-02-052021-07-30
Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC
Tesetaxel and Capecitabine, Capecitabine - Breast Cancer
Phase 3TerminatedOdonate Therapeutics, Inc.6852017-12-212021-07-30
Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer
Tesetaxel, Capecitabine - Locally Advanced Non-resectable Breast Cancer, Metastatic Breast Cancer
Phase 2UnknownGenta Incorporated2132012-05-012012-06-01
Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer
Tesetaxel, Placebo, Capecitabine - Gastric Carcinoma
Phase 2UnknownGenta Incorporated5802012-04-012012-07-24
Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer
Tesetaxel-capecitabine-cisplatin - Gastric Carcinoma
Phase 1 / Phase 2UnknownGenta Incorporated632011-05-012012-03-13
Study of Tesetaxel in Japanese Patients With Solid Tumors
Tesetaxel - Advanced Solid Tumors
Phase 1UnknownGenta Incorporated122011-04-012012-03-13
A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors
Tesetaxel plus capecitabine - Solid Tumor
Phase 1UnknownGenta Incorporated92011-03-012012-07-24
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
Tesetaxel - Prostate Cancer
Phase 2UnknownGenta Incorporated572011-02-012012-07-24
Tesetaxel as First-line Therapy for Metastatic Breast Cancer
Tesetaxel once every 3 weeks, Tesetaxel once weekly - Breast Neoplasm
Phase 2UnknownGenta Incorporated812010-11-012012-07-24
Tesetaxel for Previously Treated Patients With Bladder Cancer
Tesetaxel - Carcinoma, Transitional Cell
Phase 2UnknownGenta Incorporated332010-09-012012-07-11
Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsules
Tesetaxel 10 mg with and then without food, Tesetaxel 10 mg without and then with food - Solid Tumors
Phase 1CompletedGenta Incorporated122010-06-012012-07-24
Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer
Tesetaxel - Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction
Phase 2UnknownGenta Incorporated272010-03-012012-03-15
Phase II Study of Tesetaxel in Metastatic Melanoma
Tesetaxel - Advanced Melanoma, Cancer
Phase 2CompletedM.D. Anderson Cancer Center172010-02-012018-07-17
Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH
Tesetaxel - Melanoma
Phase 2UnknownGenta Incorporated272010-02-012011-11-08
DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors
DJ-927, capecitabine - Unspecified Adult Solid Tumor, Protocol Specific
Phase 1CompletedDaiichi Sankyo2004-02-012012-05-16
DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma
DJ-927 - Colorectal Cancer
Phase 2CompletedDaiichi Sankyo2004-02-012012-05-16

Conditions studied

Breast Neoplasms (5)  ·  Neoplasm Metastasis (3)  ·  Melanoma (2)  ·  Stomach Neoplasms (2)  ·  Carcinoma, Transitional Cell (1)  ·  Colonic Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Neoplasms (1)  ·  Prostatic Neoplasms (1)  ·  Rectal Neoplasms (1)  ·  Triple Negative Breast Neoplasms (1)  ·  Urinary Bladder Neoplasms (1)

Sponsors

Genta Incorporated (11)  ·  Odonate Therapeutics, Inc. (4)  ·  Daiichi Sankyo (2)  ·  M.D. Anderson Cancer Center (1)

Countries

United States (16)  ·  South Korea (5)  ·  Taiwan (3)  ·  Australia (2)  ·  Canada (2)  ·  Germany (2)  ·  Italy (2)  ·  Singapore (2)  ·  Spain (2)  ·  Austria (1)  ·  Belgium (1)  ·  Czechia (1)  ·  France (1)  ·  Hungary (1)  ·  Japan (1)

Top investigators

Andrew D Seidman, MD (2)  ·  Jaffer Ajani, MD (2)  ·  Joseph O'Connell, M.D. (2)  ·  Joseph O'Connell, MD (2)  ·  Agop Y Bedikian, MD (1)  ·  Agop Y. Bedikian, MD, BS (1)  ·  Chris H. Takimoto, MD, PhD, FACP (1)  ·  Dean F Bajorin, MD (1)  ·  Harry W Alcorn, PharmD (1)  ·  Lee S Schwartzberg, MD, FACP (1)  ·  Michael J Morris, MD (1)  ·  Peter Cheverton, MD, ChB, MMED, RadT (1)  ·  Sun Young Rha, MD, PhD (1)

Results publications

PMID 21547572